R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
Year: 2020
Type: review
Abstract: ABSTRACT: Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. The detailed mechanism underlying R-CHOP resistance has not been well defined. For this review, we conducted a thorough search for literature and clinical trials involving DLBCL resistance. We discussed DLBCL biology, epigenetics, and aberrant signaling of the B-cell receptor (BCR), phosphatidylinositol 3-kinase (PI3K)/Akt, nuclear factor kappa light chain enhancer of activated B-cells (NF-κB), and the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathways as defining mechanisms of DLBCL heterogeneity and R-CHOP resistance. The cell of origin, double- or triple-hit lymphoma and double-protein-expression, clonal evolution, tumor microenvironment, and multi-drug resistance help to contextualize DLBCL resistance in an (epi)genetically and biologically comparative manner. With better understanding of the biological and molecular landscape of DLBCL, a more detailed classification system and tailored treatments will ideally become available to further improve the prognosis of DLBCL patients.
Source: Chinese Medical Journal
Authors: Liang Wang, Lin-Rong Li
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: diffuse large B-cell lymphoma, relapsed/refractory lymphoma, B cell receptor signaling, PI3K/Akt signaling, NF-κB signaling, JAK/STAT3 signaling, epigenetics, clonal evolution, tumor microenvironment, drug resistance, double-hit lymphoma, triple-hit lymphoma, cell of origin, lymphoma heterogeneity
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W3191908762
